01'2*33%)...2020/10/06 · nantkwest presentation – october 2020 nantkwest leading clinical...
TRANSCRIPT
!"##"$%"&'(%$)*+,'-",,*,+$'./"$+01'2*33%)
!
!"#$%&'()*(+,+,!"#$"%&'!(
NantKwest Presentation – October 2020
General DisclaimerNot all product candidates and/or services referenced in these slides are proprietary to NantKwest and may be owned or controlled by our affiliates or third parties.
FORWARD-LOOKING STATEMENTS
These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, that are based on managements’ beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to:
• our ability to pioneer immunotherapy, harness the power of the innate immune system, implement precision cancer medicine and change the current paradigm of cancer care;• our ability to implement and support the Joint COVID-19 collaboration;• any impact of the COVID-19 pandemic, or responses to the pandemic, on our business, clinical trials or personnel;• our expectations regarding the potential benefits of our strategy and technology;• our expectations regarding the operation of our product candidates and related benefits;• our ability to utilize multiple modes to induce cell death;• our beliefs regarding the benefits and perceived limitations of competing approaches, and the future of competing technologies and our industry;• details regarding our strategic vision and planned product candidate pipeline, including that we eventually plan to advance therapies for virally induced infectious diseases;• our beliefs regarding the success, cost and timing of our product candidate development activities and current and future clinical trials and studies, including study design;• our expectations regarding our ability to utilize the phase I and II aNK and haNK clinical trials data to support the development of all of our product candidates, including our haNK, taNK and t-haNK product candidates;• the timing or likelihood of regulatory filings or other actions and related regulatory authority responses, including any planned investigational new drug, or IND, filings or pursuit of accelerated regulatory approval pathways or orphan drug status and breakthrough therapy
designations;• our ability to implement an integrated discovery ecosystem and the operation of that planned ecosystem, including being able to regularly add neoepitopes and subsequently formulate new product candidates;• the ability and willingness of strategic collaborators, including certain affiliates of NantWorks, LLC, or NantWorks, to share our vision and effectively work with us to achieve our goals;• the ability and willingness of various third parties to engage in research and development activities involving our product candidates, and our ability to leverage those activities;• our ability to attract additional third party collaborators;• our expectations regarding the ease of administration associated with our product candidates;• our expectations regarding the patient compatibility associated with our product candidates;• our beliefs regarding the potential markets for our product candidates and our ability to serve those markets;• our ability to produce an “off-the-shelf” therapy;• our beliefs regarding the potential manufacturing and distribution benefits associated with our product candidates, and our ability to scale up the production of our product candidates;• our plans regarding our manufacturing facility and our belief that our manufacturing is capable of being conducted in-house;• our belief in the potential of our aNK cells as a technology platform, and the fact that our business is based upon the success of our aNK cells as a technology platform;• our aNK platform and other product candidate families, including genetically modified taNK, haNK and t-haNK product candidates, will require significant additional clinical testing;• even if we successfully develop and commercialize our aNK product candidate, we may not be successful in developing and commercializing our other product candidates either alone or in combination with other therapeutic agents;• the ability to obtain and maintain regulatory approval of any of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate;• our ability to commercialize any approved products;• the rate and degree of market acceptance of any approved products;• our ability to attract and retain key personnel;• the accuracy of our estimates regarding our future revenue, as well as our future operating expenses, capital requirements and needs for additional financing;• our ability to obtain funding for our operations, including funding necessary to complete further development and any commercialization of our product candidates;• our ability to obtain and maintain intellectual property protection for our product candidates and not infringe upon the intellectual property of others;• our expected use of the net proceeds to us from this offering;• regulatory developments in the United States, or U.S., and foreign countries; and• our expectations regarding the period during which we qualify as an “emerging growth company” under the JOBS Act, and a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.
Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” or similar expressions and the negatives of those terms.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other risks regarding our business are described in detail in NantKwest’s Securities and Exchange Commission filings, including in NantKwest’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. We encourage you to review NantKwest’s SEC filings in order to understand these risks. These forward-looking statements speak only as of the date thereof, and we disclaim any obligation to update these statements except as may be required by law. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this presentation.
Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. No representation or warranty, express or implied, is given as to the completeness or accuracy of the information or opinions contained in this document and we do not accept any liability for any direct, indirect or consequential loss or damage arising from reliance on such information or opinions. Past performance should not be taken as an indication or guarantee of future performance. You should read this presentation completely and with the understanding that our actual future results may be materially different from what we expect.
2
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'($)!"$*+",)%-,,'+).',,).,-#-/",)0$"1')2,"$34+5
5
!"#$%"#&'())*+,-./01'233456-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
!"#$%&'() *"+,#%-+&'() ./01%-+&'() !"#2%-+&'() 3+45()
<-.@-1':-11':0D60/-'EE
<-50/505+B'D0*B.-05+B':0D60/-'EE
F!G:
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
"<;K'<715+N1-'<?-1>=0E!$'%O'PQPQ
#>1+C'F7=>./ M-=05>1>R+B'F7=>./
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
!"#$%#&'()'*(+#)',-."/
!"#$!
!%$&'!%$&(
!%$&)
*('23#23#23#*('24#24#24#24#
*('25#*( 23#23#23#*(*(*(*(*( 24#24#24#24#*(*(
*( 25#25#
E;4PS!"#
!"#$%&'((&'()
!"*+,
!"#$
!"!"#!"#$%$%$%$%-./012345
643712'-./012345-./012345-./012345-./012345-./012345
643712'643712'8719':155'8719':155';/.1643712'643712'643712'643712'643712'643712'643712'643712'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155';/.1;/.1;/.1;/.1!"*+,&'!"#$%&'((&'() !"#$%#&'()'*(
!"#$%&
67-898:87;6998:5<5=4 "8<8>
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'($)!"$*+",)%-,,'+).',,).,-#-/",)0$"1')2,"$34+5
6
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
3+45()
"<;K'<715+N1-'<?-1>=0E!$'%O'PQPQ
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
6789:8;<-=<>-,8=<?@A7B
!"#$!
!%$&'!%$&(
!%$&)
*('23#*('24#
*('25#
E;4PS!"#
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
3+45()
"<;K'<715+N1-'<?-1>=0E!$'%O'PQPQ
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
6789:8;<-=<>-,8=<?@A7B6789:8;<-=<>-,8=<?@A7B
!"#!"#$!!
!%$&'&'&'!%$&(
!%$&)
*('23#23#23#*(*(''24#24#24#24#
*(24#
*(24#
'25#25#*( 23#23#23#*(*(*(*(*( 24#24#24#24#*(*(
*( 25#25#
6789:8;<-=<>-,8=<?@A7B6789:8;<-=<>-,8=<?@A7B
E;E;4PSPS!"#
!"#$%"#&'())*+,-./01'233456-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
!"#$%&'((&'()!"*+,
!"#$!"#$!"!"#!" $%&'()*+,-./!"!"
!"#$!"#$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$%
!"#$%&'() *"+,#%-+&'() ./01%-+&'() !"#2%-+&'()
<-.@-1':-11':0D60/-'EE
<-50/505+B'D0*B.-05+B':0D60/-'EE
F!G:
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
#>1+C'F7=>./ M-=05>1>R+B'F7=>./
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
! Innate! Rapid killing! Activating & Inhibitory Receptors
!"#$%&'($)6#-7'+(",)!%89:);"($'+)0$'5).',,)<-#'
7
! Discovered 1992 human NK stem cell! Loss of major inhibitory receptors! Preserved activating receptors: NKG2D,
NKp30, NKp44, NKp46! Abundant perforin / granzyme! Always switched on! Rapid killing! Rapid doubling*
NantKwest Universal NK-92 Cell LineOff The Shelf, Cryopreserved
'()(*+,+-./0+'$*-1$2'()(*+,+-./0+'$*-1$2%345*36+&-66$*+0$66
Donor / iPSC Derived Natural Killer Cell (NK Cell)
!"#$%&'((&'()
*+,)'()(*+,+-./0+'$*-1$2
!"-.+
'()(*+,+-./0+'$*-1$2!"#$
!"#$%&'((&'()
!"*+,
#-./
!"!"#!"#$%-./012345
643712'-./012345-./012345-./012345-./012345-./012345
643712'643712'8719':155'8719':155';/.1643712'643712'643712'643712'643712'643712'643712'643712'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155';/.1;/.1;/.1;/.1!"*+,&'!"#$%&'((&'()
8*+(,*-$%(,$#9*:#$;<#1%;,-$=*>,.1())
NantKwest Presentation – October 2020
NantKwest Leading Clinical Stage Platform for Off-The-Shelf Natural Killer Cells
6
aNK(NK-92) haNK PD-L1
t-haNKCD-19t-haNK
HER2t-haNK
EGFRt-haNK
Clinical Indication Core Universal Cell Line Merkel Cell
1L, 2L, 3LPancreatic,
TNBC, & NSCLC
Lymphoma BreastGlioblastoma Head & Neck
Current Status Universal NK Cell Line Phase II Phase II Phase I
Breast: IND, Q4 2020
Glioblastoma:Phase I
IND Pending
Innate Immunity Without Major Inhibitory Receptors (e.g. NKG2D)
✓ ✓ ✓ ✓ ✓ ✓
High-Affinity CD16 X ✓ ✓ ✓ ✓ ✓erIL2 X ✓ ✓ ✓ ✓ ✓CAR Insertion(s) X - PD-L1 CD19 HER2 EGFR
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
4+5)67"&)'8"+9%5:'-,%5%;+,'2)+:"'<,+)#=$3'#=$'>##?./"?2/",#'4+)*$+,'6%,,"$'-",,&'7%)/'-=33"$;%+,'2;+,"'@A<'A+5*#+;)*$%5:
@
:2F?#2131201>'V'O14>FS7?S-31
!47J245'"/5512':155'T>9/./37247/?.CG4W'4.>'C24.3UJ31
!"#$%"#&'())*+,-./01'233456-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
*&';5%FF
*&';5%FF
*&';5%F*&';5%F
E!$'D-*C+*R
V&$7.*2%(-%>.D.)",/.-*
BG431'='V'==':5/./<45',1015?#91.7
012
0322
+%AX'S +%+%
";:2(,*.<*A(99)*BC:-$-)%(,(C*%.*0D(,*?4*+#%-($%)*E-$1(*34!@
4!"#$5$67&89$:&4!"#$5$;<.(=:!"#
";:2(,*.<*F.)()*BC:-$-)%(,(C
*+,,-./01234/12-356736189:1/;9.08<3"1/020;=
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'($)!"$*+",)%-,,'+).',,).,-#-/",)0$"1')2,"$34+5
G
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
!"#$%"#&'())*+,-./01'233456-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
!"#$%&'((&'()!"*+,
!"#$!"#$%&'()*+,-./0.-1+,&2+//&3)(+
!"#$%
!"#$%&'() *"+,#%-+&'() ./01%-+&'() !"#2%-+&'()
<-.@-1':-11':0D60/-'EE
<-50/505+B'D0*B.-05+B':0D60/-'EE
F!G:
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
#>1+C'F7=>./
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
!"#$%"#&'())*+,-./01'2334)*+,-./01'2334)*+,-./01'233 56-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
!"#$%&'((&'()!"*+,
!"#$!"!"!" $%&'()*+,-./$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./!"!"
!"#$!"#$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$%
!"#$%&'() *"+,#%-+&'() ./01%-+&'() !"#2%-+&'()
<-.@-1':-11':0D60/-'EE
<-50/505+B'D0*B.-05+B':0D60/-'EE
F!G:
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
#>1+C'F7=>./
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
3+45()
"<;K'<715+N1-'<?-1>=0E!$'%O'PQPQ
6789:8;<-=<>-,8=<?@A7B
!"#$!
!%$&'!%$&(
!%$&)
*('23#23#23#*('24#24#24#24#
*('25#*( 23#23#23#*(*(*(*(*( 24#24#24#24#*(*(
*( 25#25#
6789:8;<-=<>-,8=<?@A7B6789:8;<-=<>-,8=<?@A7B
E;4PS!"#
M-=05>1>R+B'F7=>./
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'($)254<5,'$"5=)> ?!@)A'"+=B'645=).=$4C,#')D#:"#0'+)!"$;5"/)%,//'5)0'//()EB80'!%F
H
!"#$%&'()*+',*-.#&/+#&'0*1(.(2#$3)
4'5+'.(,*6789! :3$,;.#&$'
!"#$%&'(*6',;.(,
6,>?@>AB$!BC$D>!BEFG,/
FG(+!
F,+#1
F,+#H
F,+#I
-8&9(.-8&9H.
-8&93.
#$"%&!"#
6,>?@>AB$!BC$
!!"6,>?@>AB$!BC$6,>?@>AB$!BC$6,>?@>AB$!BC$
!"#$%&
<#(=*!(>>*?(=$3"*8@
!"'*/00'12#345674'348'1496:;</4='>6=;'!?!@'A97#96/=39B'CDE,F'G/863
H,F'E .,'83B5I
*9B7#9/5/9J/8'GE:/!"A978K:=
%&'()!*+(,,$
!"#$%&
!"!#$%&'$()$*$+,-
*+$'+/#0/=674*+F)L'5/0/:=674
C&D' C&4EF
?K=707M7K5'N'?007M/4/6:?#;/9/565
&./0!1 &./0!1
1'G7+)
T'8/.L51'T#G1213/3':?551<7/?.'B2?0/>13'YSA%',?313'?U'AZA%H 6S<1!"
W%*"%@X%>"2.2%@B@X!
68A*1(+,"*BC*DEDC
D422/12'T>>21331> B2?#127F
*5>;=;-5<45 D.>1+3-.05-K';>*R'1+,-C
/<&'<45J%G7<4-=8< A*60*B-C':?5>@+*- T :6-=>@+*-K'A*60*B-C'(+11+*R
0548:<=-=8< !>*437*B5+>*01'E*6+I+5>.?'(ESK'L711?'"B5+,05-C'!(':-11
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'($)!"$*+",)%-,,'+).',,).,-#-/",)0$"1')2,"$34+5
!4
!"#$%"#&'())*+,-./01'233456-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
!"#$%&'() *"+,#%-+&'() ./01%-+&'() !"#2%-+&'() 3+45()
<-.@-1':-11':0D60/-'EE
<-50/505+B'D0*B.-05+B':0D60/-'EE
F!G:'U'!#:;:
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
"<;K'<715+N1-'<?-1>=0E!$'%O'PQPQ
#>1+C'F7=>./ M-=05>1>R+B'F7=>./
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
'023,2()$*)4$%2*)56708
!"#$!
!%$&'!%$&(
!%$&)
*('23#23#23#*('24#24#24#24#
*('25#*( 23#23#23#*(*(*(*(*( 24#24#24#24#*(*(
*( 25#25#
E;4PS!"#
'023,2()$*)4$%2*)56708'023,2()$*)4$
!"#$%&
!"#$%&'((&'()
!"*+,
!"#$
!"!"#!"#$%$%$%$%-./012345
643712'-./012345-./012345-./012345-./012345-./012345
643712'643712'8719':155'8719':155';/.1643712'643712'643712'643712'643712'643712'643712'643712'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155'8719':155';/.1;/.1;/.1;/.1!"*+,&'!"#$%&'((&'()
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'($)!"$*+",)%-,,'+).',,).,-#-/",)0$"1')2,"$34+5
!!
!"#$%"#&'())*+,-./01'233456-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
!"#$%&'((&'()!"*+,
!"#$!"#$%&'()*+,-./0.-1+,&2+//&3)(+
!"#$%
!"#$%&'() ./01%-+&'() !"#2%-+&'() 3+45()
<-.@-1':-11':0D60/-'EE
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
"<;K'<715+N1-'<?-1>=0E!$'%O'PQPQ
#>1+C'F7=>./ M-=05>1>R+B'F7=>./
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
6789:8;<-=<>-,8=<?@A7B
!"#$!
!%$&'!%$&(
!%$&)
*('23#*('24#
*('25#
E;4PS!"#
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%"#&'())*+,-./01'2334)*+,-./01'2334)*+,-./01'233 56-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
!"#$%&'((&'()!"*+,
!"#$!"!"!" $%&'()*+,-./$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./!"!"
!"#$!"#$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$%
!"#$%&'() ./01%-+&'() !"#2%-+&'() 3+45()
<-.@-1':-11':0D60/-'EE
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
"<;K'<715+N1-'<?-1>=0E!$'%O'PQPQ
#>1+C'F7=>./ M-=05>1>R+B'F7=>./
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
6789:8;<-=<>-,8=<?@A7B6789:8;<-=<>-,8=<?@A7B
!"#!"#$!!
!%$&'&'&'!%$&(
!%$&)
*('23#23#23#*(*(''24#24#24#24#
*(24#
*(24#
'25#25#*( 23#23#23#*(*(*(*(*( 24#24#24#24#*(*(
*( 25#25#
6789:8;<-=<>-,8=<?@A7B6789:8;<-=<>-,8=<?@A7B
E;E;4PSPS!"#
*"+,#%-+&'()
<-50/505+B'D0*B.-05+B':0D60/-'EE
F!G:'U'!#:;:
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
2:"(')?)G)?H)1$;+=).46</'$'+I!" !"#$%&'%('$)*$'%+$*),*)*"-%.)#-'$)*"-%/)#-$'%
!3
6>@I>,//A@B$J>,,$KL>MAM!N$L/ABI$.<O-KP$QF$8@+!N$-BC,R,BC,B:$.!CA@N@IA/:$S//,//G,B:
7&3)#*F&'(
<(.$',*F&'(*$3*G3(+#(3
!"#$%&'()*&#+,(-.(./.01%).,(2*.'(1&34"0%'5($2&(,%66.0.'$(1+%'%1"+($0%"+)(")(10&))($0%"+(1&34"0%)&')(3"7(4&$.'$%"++7()#55.)$(3%)+.",%'5()%3%+"0%$%.)("',(,%66.0.'1.)8
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
.0),$%1%2%13%4*567%/&89:$*$6;!" !"#$%&'%('$)*$'%+$*),*)*"-%.)#-'$)*"-%/)#-$'
!5
TM,>!NN$KL>MAM!N
81<?.>';/.1'?2'*214712[012455'8J20/045
!"#$%&'()*&#+,(-.(./.01%).,(2*.'(1&34"0%'5($2&(,%66.0.'$(1+%'%1"+($0%"+)(")(10&))($0%"+(1&34"0%)&')(3"7(4&$.'$%"++7()#55.)$(3%)+.",%'5()%3%+"0%$%.)("',(,%66.0.'1.)8
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
.0),$%1%2%13%4*567%/&89:$*$6;!" !"#$%&'%('$)*$'%+$*),*)*"-%.)#-'$)*"-%/)#-$'
!6
TM,>!NN$KL>MAM!N
81<?.>';/.1'?2'*214712[012455'8J20/045
!"#$%&'()*&#+,(-.(./.01%).,(2*.'(1&34"0%'5($2&(,%66.0.'$(1+%'%1"+($0%"+)(")(10&))($0%"+(1&34"0%)&')(3"7(4&$.'$%"++7()#55.)$(3%)+.",%'5()%3%+"0%$%.)("',(,%66.0.'1.)8
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'#()*+&,-&./012,32&'3&()*+&4&!"#$%&5(16703,8'&98(,:,'32
!7
>6'20(+,+,?<0@(+,+,
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%#$#&'()$*'+"$#&'(,$*'"+"#$%&'&()*+$%,-./.*0.%&''&$(*&(*"1/&.(/'*2&/3*4<J 5&(.*6./1'/1/&7*"1(7#.1/&7*8&'.1'.
!4I7I34!?
! #' ())*+)(,+- C9D (E F34-$)4G 7=H , =I: ./,0 (12('3+14('3*+(,/3 3('3+* (30/+2+1 1/5+(5+ 36',*67
! 8 5/')7+ 4(,/+', 1+96'5,*(,+1 (' 6')6/') 36947+,+*+546'5+- 62+* :; 96',05 ('1 6')6/')
"#$%&'(()*+%',-,-
!"#$%"#&'$()*+,+&-+.)$".+
"#$%&'(-"#$%&'!
E(>%*3434+JK*AK*A.$<-,:(C*0$=.-$=*"JF
EU>Y%E"%UD(6.-5.%"4%>(2.&2.
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
<)#6&8"=$6%.0),$%11%>'"):%?"*0%<$@",*')*"&#):%1#*$#*%>'"):,%A"',*%!"#$%+$*),*)*"-%.)#-'$)*"-%/)#-$'%BCD1!>EFFG
!@
>18?+,0@-3&A&
%+/122=3B?C18/-?3+.36-;1D;1;0/3718/.-1;0/3*18/-.3;.-1;-?3E0;F35-,/0;1G08-3H3#1G$71/20;1I-2
+-./0-,*102#1G$J1/20;1I-23H35-,/0;1G08-3H
345(062(./7,*102#1G$J1/20;1I-23H35-,/0;1G08-3H
*=/2+JF+DJF1,0?-B8K;0C1!"
B2?+I+.9G0/08!"
345(062(./7,*102#1G$J1/20;1I-23H35-,/0;1G08-3H
*=/2+JF+DJF1,0?-B8K;0C1!"
B2?+I+.9G0/08!"67&89$:&4!"#
B-*G4+<-)$+.3)#*$34-#
!VWXY
HUV122U)*,2#)+',%L)*,#2%W*,'(#*,#W*%X7%YRORO%>$+'.)+#(Z
3(&3'WN#,822#*+%[%\#+)$+)+',%
W*,'(#*,#
XY'V2229"05.$.,(:"$%.'$)
;6%0)$(+%'.<
'()(*+,)+,-.,/#(,010129 :/;<=*$,.(.<>*17/&?.-=*#.7#;&/&()
9 @;%A.#*$B*'&/.'*$,.(.<*/$*<1/.C*3
!"#$%&'()*&#+,(-.(./.01%).,(2*.'(1&34"0%'5($2&(,%66.0.'$(1+%'%1"+($0%"+)(")(10&))($0%"+(1&34"0%)&')(3"7(4&$.'$%"++7()#55.)$(3%)+.",%'5()%3%+"0%$%.)("',(,%66.0.'1.)8
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
<)#6&8"=$6%.0),$%11%>'"):%?"*0%<$@",*')*"&#):%1#*$#*%>'"):,%4$-%!"#$%+$*),*)*"-%.)#-'$)*"-%/)#-$'%BCD1!>EFFG
!G
HUV122U)*,2#)+',%L)*,#2%W*,'(#*,#W*%X7%YRORO%>$+'.)+#(Z
3(&3'WN#,822#*+%[%\#+)$+)+',%
W*,'(#*,#
XY'V2229"05.$.,(:"$%.'$)
;6%0)$(+%'.<
<#+#;)*+)*$H*I.#*DEDEJ
A B#<:@($6&.&:*(/"#28&0@('&"'<2#2.CA ;<4%&'($D(32#&3($6&.&:(#$(:/#&E(KA ;<4%&'($D(6/#2&.#3(&.'$00&:(#$(:/#&E(CL
F2.(G(H&&I3(32."&($6&.2.CJ
>18?+,0@-3&A&
%+/122=3B?C18/-?3+.36-;1D;1;0/3718/.-1;0/3*18/-.3;.-1;-?3E0;F35-,/0;1G08-3+.3J1/20;1I-2$G1D-?3
;F-.1J=3+.3"L%"LM3+.3"L%"!>!#LM
+-./0-,*102!.08+;-/183%0J+D+,-
%-9/+C+.08($"N
345(062(./7,*102#1G$J1/20;1I-23H35-,/0;1G08-3H
*=/2+JF+DJF1,0?-B8K;0C1
B2?+I+.9G0/0867&89$:&4!"#Z
/$#()2+<-)$+.3)#*$34-#
!VWWQ
89:*;76,<0(*=*>?@A9999"05.$.,(:"$%.'$)(;).1&',(+%'.<
!"#$%&'()*&#+,(-.(./.01%).,(2*.'(1&34"0%'5($2&(,%66.0.'$(1+%'%1"+($0%"+)(")(10&))($0%"+(1&34"0%)&')(3"7(4&$.'$%"++7()#55.)$(3%)+.",%'5()%3%+"0%$%.)("',(,%66.0.'1.)8
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
<)#6&8"=$6%.0),$%11%>'"):%?"*0%<$@",*')*"&#):%1#*$#*%>'"):,%>0"'6%!"#$%&'%('$)*$'%+$*),*)*"-%.)#-'$)*"-%/)#-$'%BCD1!>EFFG
!H
HUV122U)*,2#)+',%L)*,#2%W*,'(#*,#W*%X7%YRORO%>$+'.)+#(Z
3(&3'WN#,822#*+%[%\#+)$+)+',%
W*,'(#*,#
XY'V2229"05.$.,(:"$%.'$)
;6%0)$(+%'.<
<#+#;)*+)*$H*I.#*DEDEJ
A B#<:@($6&.&:*(/"#28&0@('&"'<2#2.CA ;<4%&'($D(32#&3($6&.&:(#$(:/#&E(KA ;<4%&'($D(6/#2&.#3(&.'$00&:(#$(:/#&E(+(
F!6&.(0&33(#7/.(L(H&&IJA ;<4%&'($D(6/#2&.#3(%&2.C(&8/0</#&:(M+N
%+/122=3B?C18/-?3+.36-;1D;1;0/3718/.-1;0/3*18/-.3O.-1;-?3E0;F31;3%-1D;3'3%08-D3+:3OF-.1J=
345(062(./7,*102#1G$J1/20;1I-23H35-,/0;1G08-3H
*=/2+JF+DJF1,0?-B8K;0C1
B2?+I+.9G0/0867&89$:&4!"#Z
J;-*2"<-)$+(*+A*$34$*+.3)#*$34-#
!VZQ89:*;76,<0(*=*>?@A9999"05.$.,(:"$%.'$)(;).1&',(+%'.<
OP%Q'R360K9/'N'O$,&%%%!"#$%&%'()"&*%+&,(-&.*#'(/*+%0
!"#$%&'(&)(#"*#+&),#%"#(&%,#*")#-&%.,'%$#.'#%/.)(#0.',#")#1),&%,)#2,%&$%&%.+#-&'+),&%.+#+&'+,)
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'($)!"$*+",)%-,,'+).',,).,-#-/",)0$"1')2,"$34+5
34
!"#$%"#&'())*+,-./01'233456-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
!"#$%&'((&'()!"*+,
!"#$!"#$%&'()*+,-./0.-1+,&2+//&3)(+
!"#$%
!"#$%&'() ./01%-+&'() !"#2%-+&'() 3+45()
<-.@-1':-11':0D60/-'EE
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
"<;K'<715+N1-'<?-1>=0E!$'%O'PQPQ
#>1+C'F7=>./ M-=05>1>R+B'F7=>./
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
6789:8;<-=<>-,8=<?@A7B
!"#$!
!%$&'!%$&(
!%$&)
*('23#*('24#
*('25#
E;4PS!"#
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%"#&'())*+,-./01'2334)*+,-./01'2334)*+,-./01'233 56-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
!"#$%&'((&'()!"*+,
!"#$!"!"!" $%&'()*+,-./$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./!"!"
!"#$!"#$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$%
!"#$%&'() ./01%-+&'() !"#2%-+&'() 3+45()
<-.@-1':-11':0D60/-'EE
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
"<;K'<715+N1-'<?-1>=0E!$'%O'PQPQ
#>1+C'F7=>./ M-=05>1>R+B'F7=>./
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
6789:8;<-=<>-,8=<?@A7B6789:8;<-=<>-,8=<?@A7B
!"#!"#$!!
!%$&'&'&'!%$&(
!%$&)
*('23#23#23#*(*(''24#24#24#24#
*(24#
*(24#
'25#25#*( 23#23#23#*(*(*(*(*( 24#24#24#24#*(*(
*( 25#25#
6789:8;<-=<>-,8=<?@A7B6789:8;<-=<>-,8=<?@A7B
E;E;4PSPS!"#
*"+,#%-+&'()
<-50/505+B'D0*B.-05+B':0D60/-'EE
F!G:'U'!#:;:
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'&()*+,-&)./)012,%)34567)28)012$%&)4&9,'2:&);1&,-')!,8<&1)=2'+)+,4>)?)@:&%A#,/B)C,',)D"<E&(*1"#2-289)C2-&,-&)!"8'1"%)3F6G7),8()!"#$%&'&)H&-$"8-&)3IIG7)28)@(:,8<&()J&',-','2<)C2-&,-&
!4I7I343!
64!/,$-Q$<[RN@>!:@>F$P>A!N$AB$SCM!B+,C$P>ARN,$",I!:AM,$\>,!/:$O!B+,>
#7I[-B5/'\+56':>=N1-5-'>.'D0.5+01'2,-.011'S-/N>*/-'8+.S:9 ]'T'^'8]_`9
#7I[-B5/'\+56':>=N1-5-'S-/N>*/-'8+.S:9 P'T'^'8PP`9
#7I[-B5/'\+56'$+/-0/-':>*5.>1'8+.S:9 Y'T'^'8Y^`9
<-C+0*'$7.05+>*'>3'S-/N>*/-'8+.S:9 WPa_'=>*56/
<-C+0*'D.>R.-//+>*4L.--'/7.,+,01'8+.S:9 WXa_'=>*56/
<-C+0*'2,-.011'#7.,+,01 W^aP'=>*56/
9 !$45)6,78-98$++5-6,.8$$,+*8:5:);,<)+,=3>?,@-6(A+ 2&/3*@$45)6,-:$8);;,+*8:5:);,-.,=B>0,@-6(A+,(-,4)($
P>ARN,$",I!:AM,$\>,!/:$O!B+,>D.>R.-//+>*'L.--'#7.,+,01'7/+*R'+.S:
L$>;29-)M(C
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
.45='$-$-7')>#",?(-()-#)@!A.):59 <-#')4+)B+'"$'+
J*(2$61K+7LMM5)(M$2-#G,A-6$32:
! N/+O-4;+3+M$2-3)+(E+=9P=+M()4;G+<=>?@36'A/1+'3+@/',+*2(7@<B#C-@:;DE":FD;C@2+*5G5@HDE@96',05@<=>?@B#-@>DI"EDEC@A6*@30+96,0+*(4J
! HD+#(MF6$4$+*$GF()G$G
33
()4 8AB,$@>$D>,!:,>]$P>ARN,$",I!:AM,$\>,!/:$O!B+,>2,-.011'#7.,+,01
Z).&2.%#2.%5&#*("-%30.-%6$&3(-7%5"/,&$(2"-2%&5$"22%6(44.$.-*%5)(-(5&)%*$(&)2
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&''&(&'''&)#*+,-./%+&01.*.2#1&34.#1&.*&5!" 6.*%&,4&74%#8%4&39:0&;.8"&!<=6>&8="#9?
!4I7I3435
DMNOCEE!"#$%&'($)*#"'+)*,-#)*#',)'./'01212'
3%&,4$&#-5
CE9DEP67!('+)*,-#)*#
QCCOEEE6$"8#&#-'9$&,#)&%
DMP:#&$%&$&,*''$)-';#*<""#)&'
($%#%
A ?(,&+'*23$03())&$'*H3((*);3/&/+>*$H*CKRM*
=$'#5) H2#7(=(,&+'*$/(3+>>*);3/&/+>*$H*CNRD*=$'#5)*#$*,+#(*.$=2+3()*H+/$3+S>"*
#$*<+.&#;T;=+S*UV3$,(>/"W
A O/3&:($.(6'$4232.C('&3<0#3($D(:<'/%0&("$460&#&('&36$.3&3(2.(#7&(&P60$'/#$'@(Q7/3&(R("02.2"/0(#'2/03($.(4&#/3#/#2"(#'260&(.&C/#28&(%'&/3#*(+*#5&3,*>&'(*=(#+)#+#&.*#3&2>(*'(0+#&/(*S3(+)#*.+'.(3*#3&+>*&)*
.;33('#>"*S(&'0*,()&0'(,*+)*+*
3+',$=&T(,*#3&+>*;)&'0*:A9FC*#95+8@*&'*
.$=S&'+#&$'*#5(3+2"*&'*2+#&('#)*X*DBC
>&'(*$3*03(+#(3*V8Y!R
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'($)!"$*+",)%-,,'+).',,).,-#-/",)0$"1')2,"$34+5
36
!"#$%"#&'())*+,-./01'233456-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
!"#$%&'((&'()!"*+,
!"#$!"#$%&'()*+,-./0.-1+,&2+//&3)(+
!"#$%
!"#$%&'() ./01%-+&'() !"#2%-+&'()
<-.@-1':-11':0D60/-'EE
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
#>1+C'F7=>./ M-=05>1>R+B'F7=>./
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
*"+,#%-+&'()
<-50/505+B'D0*B.-05+B':0D60/-'EE
F!G:
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%"#&'())*+,-./01'2334)*+,-./01'2334)*+,-./01'233 56-4#6-13
!057.01'(+11-.'8!(9':-11';+*-
!"#$%&'((&'()!"*+,
!"#$!"!"!" $%&'()*+,-./$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./!"!"
!"#$!"#$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$%
!"#$%&'() ./01%-+&'() !"#2%-+&'()
<-.@-1':-11':0D60/-'EE
G.-0/5
H1+>I10/5>=0D60/-'E
$G;:;E!$'"756>.+J-CK'LEM
#>1+C'F7=>./ M-=05>1>R+B'F7=>./
5$46'&7&.328&(9&/:&'(2.(;/#<'/0(=200&'(5&003
*"+,#%-+&'()
<-50/505+B'D0*B.-05+B':0D60/-'EE
F!G:
3+45()
"<;K'<715+N1-'<?-1>=0E!$'%O'PQPQ
6789:8;<-=<>-,8=<?@A7B
!"#$!
!%$&'!%$&(
!%$&)
*('23#23#23#*('24#24#24#24#
*('25#*( 23#23#23#*(*(*(*(*( 24#24#24#24#*(*(
*( 25#25#
6789:8;<-=<>-,8=<?@A7B6789:8;<-=<>-,8=<?@A7B
E;4PS!"#
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
6789:8;<-=<>-,8=<?@A7B6789:8;<-=<>-,8=<?@A7B6789:8;<-=<>-,8=<?@A7B
!"#$%&
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
>0$%D#*)99$6%.&*$#*"):%&H%+$8&'7E!"I$%J)*5'):%K"::$'%/$::,
37
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
;)',38)<1&=32&5>'37,81&?82,6(1@&*)'/2)<&+,<<12&51<<&A61*+BC5>'37,81#98@/61@&D1E32>#<,71&*)'/2)<&+,<<12&51<<-&?F(,:,'&?8()861@&
;1-038-1-&GH),8-'&D>1<3,@&$1/71E,)&,8&!21#5<,8,6)<&D3@1<-
3?
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
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
C7"+-"#)."#/'+
3@
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
4"@#"H"-)#*%/7*&*&L"-"*7%&H%+E-$JK%/$::,%A'&8%M::&@$#$"-%&'%M5*&:&@&5,%M90$'$,",%4&5'-$
TW
D422/12'T>>21331> B2?#127F
*5>;=;-5<45 D.>1+3-.05-K';>*R'1+,-C
/<&'<45J%G7<4-=8< A*60*B-C':?5>@+*- T :6-=>@+*-K'A*60*B-C'(+11+*R
0548:<=-=8< !>*437*B5+>*01'E*6+I+5>.?'(ESK'L711?'"B5+,05-C'!(':-11+B/-C6.($*7.D*1'/6E7/6.F*#('(5/-0$
3.G7.'(D*"H)&!
I0-D<'/6-.
+B/-C6.(*".D<'(D
3.G7.'(D*!
I0-D<'/6-.
!"#$%#&'()'*(+#)',-."/
=[E?!
=J?@T=J?@\
=J?@W
012345345345012365365365
01237501 3453453450101010101 3653653650101
0101 375
!"#$%#&'()'*(+#)',-."/ NOP3Q!"#
!$'#3$>*.(8@*!(>>) ?9.(8@*!(>>)
!"#$! !"#$!
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
*)8'+I1-'&!2302,1')2>&J 9*"&;1)@>D1E32>&5>'37,81&?8()861@&*)'/2)<&+,<<12&61<<-&AD#61*+B
3H
*&+,"#
?K=707M7K5'S'?007M/46:*B=7T64/'1496:;/8'U=/<'*/005
+(,->M(,#9*R9..CI*A.,C*R9..C
*B=7T64/'1496:;/8*075/8'UB5=/<'-GA'64'3'V72 !*?W'C45/9=674'A7=/4=630 !*K99/4='U=3=K5 !#P3>-1?=
*0646:30'C486:3=674S 0D#,-#$TS U;9%->9(*UV(9.:#S BUO
'023,2()$*)4$%2*)56708
!"#$!
!%$&'!%$&(
!%$&)
*('23#23#23#*('24#24#24#24#
*('25#*( 23#23#23#*(*(*(*(*( 24#24#24#24#
*( 25#25#
E;4PS!"#
'023,2()$*)4$
!"#$%&
*&+,"#<-=>.?':?5>@+*-'A*.+B6-C'
!057.01'(+11-.
6%K=<:95%6L&5>5;=;%!89954-=8<%*>8@=J5;%I+#M%"8;5;%8N%#O#MA 3+45()
-SQT2.T/TO$P
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
J)#*K?$,*%.'&9'"$*)'7%N 1JO%<$)67+$8&'7%/7*&I"#$%P#0)#-$6%J)*5'):%K"::$'%-$::,%B+E-$JKG
54
!"'*/00'12#345674'348'1496:;</4='>6=;'!?!@'A97#96/=39B'CDE,F'G/863
H,F'E .,'83B5I
*9B7#9/5/9J/8'GE:/!"A978K:=
%&'()!*+(,,$
!"#$%&
!"!#$%&'$()$*$+,-
*+$'+/#0/=674*+F)L'5/0/:=674
C&D' C&4EF
?K=707M7K5'N'?007M/4/6:?#;/9/565
&./0!1 &./0!1
=.>/<47/?. :5/./<45'8747J3
P@'>='<%!'<45> E!$'L+1+*R'%O'PQPQ
379-=L95%3Q598E' E!$'L+1+*R'%W'PQPW
63, E!$'L+1+*R'%P'PQPW
1'G7+)
68A*1(+,"
T'8/.L51'T#G1213/3':?551<7/?.'B2?0/>13'YSA%',?313'?U'AZA%H 6S<1!"
W%*"%@X%>"2.2%@B@X!
!"#$%&'()*+',*-.#&/+#&'0*1(.(2#$3)
4'5+'.(,*6789! :3$,;.#&$'
!"#$%&'(*6',;.(,
6,>?@>AB$!BC$D>!BEFG,/
FG(+!
F,+#1
F,+#H
F,+#I
-8&9(.-8&9H.
-8&93.
#$"%&!"#
6,>?@>AB$!BC$
!!"6,>?@>AB$!BC$6,>?@>AB$!BC$6,>?@>AB$!BC$
!"#$%&
<#(=*!(>>*?(=$3"*8@
"#$%&'()%*+,()($%#%-.$*/ 01%.2(,*3434
!"#$%&'($)!"$*+",)%-,,'+).',,).,-#-/",)0$"1')2,"$34+5
5!
L)1$G4M$)4+>-T;6-T;4GS
! N65,@9(,G*+@'(,G*(7@L/77+*@3+77@47(,A6*9@
! W/*5,@/'@0G9('@('1@A/*5,@/'@37(55@37/'/3(7@+Q4+*/+'3+
! X5,(P7/50+1@YNZ@9('GA(3,G*/')@(,@3699+*3/(7@53(7+
! [*6(1+5,@'(,G*(7@L/77+*@3+77@,0+*(4J@47(,A6*9@A*69@P6,0@
G'/2+*5(7@3+77@7/'+@('1@(776)+'+/3@\@(G,676)6G5@56G*3+
! 812('3+1@37/'/3(7@,*/(75@(3*655@9G7,/47+@/'1/3(,/6'5
! 811*+55/')@7(*)+@G'9+,@'++15@/'@567/1@('1@7/]G/1@
,G96*5@./,0@4*69/5/')@5(A+,J@('1@+AA/3(3J@1(,(@,6@1(,+
!"#$%"#&'()!"#$%&'()*+,,-./%-0/%),
1(.2&()*3#))%&*4135*6%))*7#"%
!"#$%&'((&'()!"*+,
!"#$!"#$!"!"#
!"#$!" $%&'()*+,-./!"!"
!"#$!"#$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./$%&'()*+,-./0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+0.-1+,&2+//&3)(+
!"#$%
!"#$%&'() *+,-%./&'() !"#0%./&'()
8%&9%)*6%))*6(:/('%*;;
<&%('.
=)#>?)('.>@(:/('%*;
A<767;1A*B2./>&#C%DE*F;G
0>)#D*H2@>&' G%@(.>)>I#J*H2@>&'
!"#$%&'&()*+&,-&./&%,*(,0.12%.3,4*33&%,!&33)
1"/2#%./&'()
8%.('.(.#J*:("J&%(.#J*6(:/('%*;;
H1<6*K*10676
3/45()
B87E*82).#L)%*8M%)>@(;1A N%(DM
!"#$%#&'()'*(+#)',-."/
!"#$!
!%$&'!%$&(
!%$&)
012345345345012365365365
01237501 345345345010101 36536536536501
01 375375
;7-ON!"#
*&+,"#8%@>&M*6M.>9#"%*P"&#J/%D*
1(.2&()*3#))%&
!"#$%#&'()'*(+#)',-."/
01 345345345
!"#$%#&'()'*(+#)',-."/!"#$%#&'()'*(+#)',-."/!"#$%#&'()'*(+#)',-."/!"#$%#&'()'*(+#)',-."/!"#$%#&'()'*(+#)',-."/!"#$%&